Table 1 Baseline characteristics of patients
Characteristics | Number of patients (%) | ||
|---|---|---|---|
Total (n = 33) | HR-positive /HER2-negative (n = 23) | Triple-negative(n = 10) | |
Age, median (range), years | 52(32–79) | 52(32–73) | 47(36–79) |
ECOG PS at baseline | |||
1 | 33 (100.0) | 23(100.0) | 10(100.0) |
Menopausal status | |||
Premenopausal | 2(6.1) | 1(4.3) | 1(10.0) |
Postmenopausal | 31(93.9) | 22(95.7) | 9(90.0) |
Number of metastatic sites | |||
<3 | 8(24.2) | 5(21.7) | 3(30.0) |
≥3 | 25(75.8) | 18(78.3) | 7(70.0) |
Visceral metastases | |||
Yes | 24(72.7) | 18(78.3) | 6(60.0) |
No | 9(27.3) | 5(21.7) | 4(40.0) |
Dominant metastatic sites | |||
Bone | 21(63.6) | 16(69.6) | 5(50.0) |
Liver | 11(33.3) | 9(39.1) | 2(20.0) |
Lung | 15(45.5) | 10(43.5) | 5(50.0) |
Brain | 5(15.2) | 4(17.4) | 1(10.0) |
Lymph nodes | 31(93.9) | 21(91.3) | 10(100.0) |
Previous lines of systematic treatment | |||
Median (range) | 2(1–4) | 2(1-4) | - |
1 | 16(48.5) | 11(47.8) | 5(50.0) |
2 | 9(27.3) | 4(17.4) | 5(50.0) |
≥3 | 8(24.2) | 8(34.8) | 0 |
Previous lines of chemotherapy treatment | |||
Median (range) | 1(1–3) | 1(0-3) | 1(1-2) |
0 | 11(33.3) | 11(47.8) | 0 |
1 | 10(30.3) | 5(21.7) | 5(50.0) |
≥2 | 12(36.4) | 7(30.4) | 5(50.0) |
Previous lines of endocrine treatment | |||
Median (range) | — | 1(1-4) | — |
1 | — | 14(60.9) | — |
2 | — | 5(21.7) | — |
≥3 | — | 4(17.4) | — |
Chemotherapy partner of anlotinib | |||
Taxanes | 11(33.3) | 11(47.8) | 0 |
Eribulin | 11(33.3) | 5(21.7) | 6(60.0) |
Utidelone | 6(18.2) | 5(21.7) | 1(10.0) |
Capecitabine | 5(15.2) | 2(8.7) | 3(30.0) |
Initial dose of anlotinib (mg/day) | |||
12 | 30(90.9) | 21(91.3) | 9(90.0) |
10 | 2(6.1) | 2(8.7) | 0 |
8 | 1(3.0) | 0 | 1(10.0) |
